Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Business Wire•02/10/2026•17:00 ET
0
Key Highlights
- ➤352,170 shares granted to 60 new employees under Xeris’ (XERS) Inducement Equity Plan
- ➤64,393 stock options carry a $9.25 exercise price and ten-year term
- ➤Equity awards vest in equal annual installments over three years
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2026, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options and restricted stock units for an aggregate of 352,170 shares of its common stock to 60 new employees under Xeris’ Inducement Equity Plan.
Get started
Create a free account to read the full story.